BioSpace News Archive

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, reported the grant of 33,475 restricted stock units of the company’s common stock to 10 newly hired non-executive officers of the company.

Exscientia plc announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology.

Mainz Biomed N.V. announced that Guido Baechler, Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference which takes place September 26-28, 2023 in New York City.

Asieris Pharmaceuticals has announced that the multinational Phase III clinical trial of APL-1702, a novel, non-surgical treatment of cervical high-grade squamous intraepithelial lesions, has met its primary endpoint.

iZafe Group iZafe Group AB is pleased to announce the successful implementation of their medication robot, Dosell, in Spain.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-26.

Helius Medical Technologies, Inc. announced it has signed an agreement with the School of Rehabilitation at the Université de Montréal for the purchase of ten PoNS devices to be used in a research project linked to stroke recovery.

Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on new discovery compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers.

Capsida Biotherapeutics (“Capsida”) today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the following upcoming investor and industry conferences.

Corsair Pharma, Inc. today announced the closing of its $23M Series B financing led by New Rhein Healthcare Investors.